Artificial Intelligence (AI) is ushering in a transformative era for personalized medicine by customizing therapeutic interventions based on individual patient profiles, including genetic information and environmental influences. Through the analysis of intricate biological datasets, AI significantly improves diagnostic accuracy, prognostic assessments and therapeutic planning, thereby enabling more precise patient stratification and enhanced clinical outcomes. This advancement is particularly evident in the realms of genomic analysis and pharmacogenomics. Nonetheless, the integration of AI into healthcare introduces substantial legal and ethical considerations. Foremost among these are concerns related to data privacy, security and equitable access to treatment. It is imperative to address these issues to effectively leverage the full potential of AI. Achieving this requires a reevaluation of regulatory frameworks and an enhancement of training programs for healthcare professionals. As AI continues to advance within the healthcare sector, it promises to fundamentally redefine disease management and prevention, heralding a new epoch of medical innovation.
Lakshmi Prasanthi Nori, Potti Sowmya, Tippa Madhusree and Kalidindi Venkateswara Raju1* Author informationArticle notesCopyright and License informationPDFCitations Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Kovvada, Andhra Pradesh, INDIA Corresponding author. Correspondence:, Dr. K. Venkateswara Raju M. Pharm, Ph.D, Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Kovvada, Andhra Pradesh, INDIA, Email: venkateswararaju.k@svcp.edu.in
7 March 2023 in International Journal of Applied Pharmaceutics
Vaccine development usually takes around 7 y to come to the market after getting necessary regulatory approvals. But recent pandemics like Covid, Ebola, Swine Flu, have resulted in the collaboration of efforts between the government doing investments in vaccine development, academia, regulatory bodies, and industry. This has shortened the timelines for approval for vaccines. In 2009, HINI, Swine flu vaccines took 93 d for identifying the vaccine candidate for clinical trials. In 2014, for Ebola vaccine, it was deployed while the epidemic was still going on. Ebola vaccine was developed in 5 y. In case of Covid (SARS-CoV-2) clinical trials were approved when 2 mo of the pandemic onset. Within a time of 9 mo about 138 vaccine candidates are being reviewed for approval of EUA. This highly helps in the shortening of vaccine development and necessary approval. In this paper, we focused on the regulatory framework of vaccine development in INDIA, US and EU.
21 September 2023 in International Journal of Pharmaceutical Investigation
Lakshmi Prasanthi Nori, Sheik Rehana, Anusha Penamacha, Bhanu Mounika Somalanka and K. Venkateswara RajuAuthor informationPDFCitationsCorresponding author. Correspondence: Dr. K. Venkateswara Raju Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari-534202, Andhra Pradesh, INDIA. Email: venkateswararaju.k@svcp.edu.in Author NotesReceived March 30, 2023; Revised April 20, 2023; Accepted May 01, 2023.Copyright and License informationCopyright
1 January 2024 in Brazilian Journal of Pharmaceutical Sciences
In the biopharmaceutical industry, the conventional “linear and sequential” clinical trial approach is still the norm; however, it is frequently beset by issues with patient selection, retention, and monitoring that are not up to par, leading to longer trial durations and higher trial failure rates. Artificial intelligence (AI) has the potential to reduce the duration of clinical trials significantly, expedite protocol design and study implementation, improve trial outcomes, and lower the cost of biopharmaceutical R&D. AI may also speed up clinical cycle times. Clinical trial mining, design and execution, and real-world experience analysis are all possible using AI. Major drug makers are utilizing AI to locate volunteers for clinical trials or to cut down on the number of subjects required for drug testing, which might speed up medication development and save millions of dollars. The clinical trial procedure may be enhanced by AI, but evidentiary requirements for a drug’s efficacy and safety won’t alter, according to regulators. This article discusses the application of AI, RWD, and RWE in clinical trials and how it is transforming the biopharma value chain, encompassing all pharmaceutical firms referred to as “biopharma companies” due to the inclusion of biologics in their development pipelines and within these biopharma firms, artificial intelligence (AI) is finding its way into drug research.
28 September 2016 in Indian Journal of Science and Technology
A Study on Impulse Buying Behaviour in the Backdrop of Customer Perception towards Visual Merchandising and Other Service Attributes at Organized Retail Outlets in Hyderabad